Zentalis Pharmaceuticals (ZNTL) Cash from Operations (2019 - 2026)
Zentalis Pharmaceuticals' quarterly Cash from Operations came in at 32956000.0 in Q1 2026, down 0.98% year-on-year from 33282337.42 in Q1 2025, and down 6.52% quarter-over-quarter from 30940000.0 in Q4 2025.
Zentalis Pharmaceuticals has reported Cash from Operations for 8 years, with the latest figure at 32956000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 0.98% year-over-year to 32956000.0; the trailing twelve-month figure through Mar 2026 stood at 125567000.0 (up 17.13% YoY), and the FY2025 full-year result was 125247000.0, up 26.7% from the prior year.
- Cash from Operations for Q1 2026 stood at 32956000.0, down from 30940000.0 in the prior quarter.
- The five-year high for Cash from Operations was 26963000.0 in Q3 2025, with the low at 79275000.0 in Q2 2023.
- Average Cash from Operations over 5 years is 41213882.35, with a median of 38665000.0 recorded in 2023.
- Year-over-year, Cash from Operations slumped 84.24% in 2023 and surged 55.67% in 2024.
- Tracing ZNTL's Cash from Operations over 5 years: stood at 37329000.0 in 2022, then retreated by 8.76% to 40599000.0 in 2023, then grew by 2.21% to 39702000.0 in 2024, then advanced by 22.07% to 30940000.0 in 2025, then slipped by 6.52% to 32956000.0 in 2026.
- The last three Cash from Operations figures came in at 32956000.0 (Q1 2026), 30940000.0 (Q4 2025), and 26963000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - | -32.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.96 Mn |
| Mar 31, 2026 | -32.96 Mn |
| Dec 31, 2025 | -30.94 Mn |
| Dec 31, 2025 | -30.94 Mn |
| Sep 30, 2025 | -26.96 Mn |
| Sep 30, 2025 | -26.96 Mn |
| Jun 30, 2025 | -34.71 Mn |
| Jun 30, 2025 | -34.71 Mn |
| Mar 31, 2025 | -32.64 Mn |
| Mar 31, 2025 | -32.64 Mn |
| Dec 31, 2024 | -39.70 Mn |
| Dec 31, 2024 | -39.70 Mn |
| Sep 30, 2024 | -44.05 Mn |
| Sep 30, 2024 | -44.05 Mn |
| Jun 30, 2024 | -35.14 Mn |
| Jun 30, 2024 | -35.14 Mn |
| Mar 31, 2024 | -51.97 Mn |
| Mar 31, 2024 | -51.97 Mn |
| Dec 31, 2023 | -40.60 Mn |
| Dec 31, 2023 | -40.60 Mn |
| Sep 30, 2023 | -38.67 Mn |
| Sep 30, 2023 | -38.67 Mn |
| Jun 30, 2023 | -79.28 Mn |
| Jun 30, 2023 | -79.28 Mn |
| Mar 31, 2023 | -49.28 Mn |
| Mar 31, 2023 | -49.28 Mn |
| Dec 31, 2022 | -37.33 Mn |
| Dec 31, 2022 | -37.33 Mn |
| Sep 30, 2022 | -33.20 Mn |
| Sep 30, 2022 | -33.20 Mn |
| Jun 30, 2022 | -43.03 Mn |
| Jun 30, 2022 | -43.03 Mn |
| Mar 31, 2022 | -50.20 Mn |
| Mar 31, 2022 | -50.20 Mn |
| Dec 31, 2021 | -37.02 Mn |
| Dec 31, 2021 | -37.02 Mn |
| Sep 30, 2021 | -33.49 Mn |
| Sep 30, 2021 | -33.49 Mn |
| Jun 30, 2021 | -46.11 Mn |
| Jun 30, 2021 | -46.11 Mn |
| Mar 31, 2021 | -37.47 Mn |
| Mar 31, 2021 | -37.47 Mn |
| Dec 31, 2020 | -27.36 Mn |
| Dec 31, 2020 | -27.36 Mn |
| Sep 30, 2020 | -20.56 Mn |
| Sep 30, 2020 | -20.56 Mn |
| Jun 30, 2020 | -22.03 Mn |
| Jun 30, 2020 | -22.03 Mn |
| Mar 31, 2020 | -16.87 Mn |
| Mar 31, 2020 | -16.87 Mn |
| Dec 31, 2019 | -13.19 Mn |
| Dec 31, 2019 | -13.19 Mn |
| Sep 30, 2019 | -9.99 Mn |
| Sep 30, 2019 | -9.99 Mn |
| Jun 30, 2019 | -6.96 Mn |
| Jun 30, 2019 | -6.96 Mn |
| Mar 31, 2019 | -9.01 Mn |
| Mar 31, 2019 | -9.01 Mn |